Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach

Journal of Clinical Pharmacology

Volumn 51, Issue 7, 2011, Pages 1087-1100

  Duan, John Z ^a,b   Jackson, Andre J ^a   Zhao, Ping ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b FDA/CDER/OTS/OCP ^*  (United States)

Author keywords

bioavailability; drug interaction; NONMEM; SimCyp

Indexed keywords

KETOCONAZOLE; MIDAZOLAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INTERACTION; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POPULATION PHARMACOKINETICS; SINGLE DRUG DOSE;

ALGORITHMS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 79958854645     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010377200     Document Type: Article

References (23)

1. Drusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998 ; 178: 360-367 (Pubitemid 28347917)
2. Rowland M, Tozer T Clinical Pharmacokinetics: Concepts and Applications. Media, PA: Williams & Wilkins ; 1995 :
3. Ferslew KE, Hagardorn AN, Harlan GC, et al. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci. 1998 ; 43: 1082-1085 (Pubitemid 28397197)
4. Gryn J, Gordon R, Bapat A, et al. Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant. 1993 ; 12: 217-220 (Pubitemid 23268155)
5. Kudo K, Imamura T, Jitsufuchi N, et al. Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Forensic Sci Int. 1997 ; 86: 35-41 (Pubitemid 27187313)
6. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: FDA ; 2006 :
7. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007 ; 81: 298-304 (Pubitemid 46174829)
8. Zhang L, Strong JM, Qiu W, et al. Scientific perspectives on drug transporters and their role in drug interaction. Mol Pharm. 2006 ; 3: 62-69 (Pubitemid 43331752)
9. Zhao P, Ragueneau-Majlessi I, Zhang L, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol. 2009 ; 49: 351-359
10. Kuhlmann J. Drug interaction studies during drug development: which, when, how?. Int J Clin Pharmacol Ther. 1994 ; 32: 305-311 (Pubitemid 24172590)
11. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: FDA ; 1999 :
12. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?. J Clin Pharmacol. 2006 ; 46: 1268-1289 (Pubitemid 44564356)
13. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007 ; 6: 140-148 (Pubitemid 46745341)
14. Jamei M, Marciniak S, Feng K, et al. The SimCyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009 ; 5: 211-223
15. Turner D. SimCyp User Manual. 2008 ;:
16. Stoch SA, Friedman E, Maes A, et al. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol. 2009 ; 49: 398-406
17. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997 ; 283: 1552-1562 (Pubitemid 28016533)
18. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003 ; 43: 831-839 (Pubitemid 36886103)
19. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999 ; 66: 461-471
20. Lee JI, Chaves-Gnecco D, Amico JA, et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002 ; 72: 718-728 (Pubitemid 36021011)
21. Chien JY, Lucksiri A, Ernest CS, et al. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos. 2006 ; 34: 1208-1219 (Pubitemid 43922328)
22. Johnson TN, Kerbusch T, Jones B, et al. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm Stat. 2009 ; 8: 186-202
23. Vossen M, Sevestre M, Niederalt C, et al. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model. 2007 ; 4: 13